期刊文献+

卵巢交界性肿瘤复发相关因素临床特点及处理原则 被引量:6

Recurrence of borderline ovarian tumor:the related factors,clinical characteristics and management strategy
原文传递
导出
摘要 卵巢交界性肿瘤总体复发率为11%。复发的不良因素主要包括:进展期、浸润性种植、病灶残留。保守性手术的复发率高,但大部分复发仍为交界性,且局限于卵巢内,不影响生存率。对于卵巢内复发,渴望保留生育功能的年轻患者,如没有浸润性种植并可接受长期严密随访,可再次行保守性手术。如果存在浸润性种植、卵巢外复发或进展为恶性卵巢癌,应行肿瘤细胞减灭术。目前没有证据表明术后化疗对于复发性交界性肿瘤有益。 The overall recurrence rate for borderline ovarian tumors is estimated to be 11%. Major nega- tive prognostic factors for recurrence are more ad- vanced disease, the presence of invasive implants and/or the presence of postoperative macroscopic re- sidual disease. The rate of recurrence is higher after conservative surgery. Most of these recurrences are borderline type and are found on the spared ovary with an excellent long-term survival. If a relapse in the remaining ovary occurs without invasive implants, further conservative management may be offered to patients who are young, desire fertility pres- ervation, and engage in long-term follow-up. When extraovarian recurrence, invasive implants or inva- sive disease occur, extensive cytoreductive surgery is the treatment option of choice. To date, there is no proven benefit from adjuvant chemotherapy.
出处 《中国实用妇科与产科杂志》 CAS CSCD 北大核心 2015年第11期1005-1008,共4页 Chinese Journal of Practical Gynecology and Obstetrics
关键词 卵巢交界性肿瘤 复发 处理 borderline ovarian tumor recurrence management
  • 相关文献

参考文献9

  • 1du Bois A, Ewald-Riegler N, du Bois O et al. Borderline tumors of the ovary: a systematic review [J]. Geburtsh Frauenheilk, 2009, 69:807-833.
  • 2Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indi- cators[J]. Hum Pathol, 2000, 31: 539-557.
  • 3Seidman JD, Cho KR, Ronnett BM, et al. Surface epithelial tu- mors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, eds. Blausteins pathology of the female genital tract [ M ].6th ed. New York: Springer Science Business Medica, 2011:680-772.
  • 4Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases[J]. Am J Surg Patho1,2004,28:1311-1318.
  • 5Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants [ J ]. Oncologist, 2009, 14:591-600.
  • 6Morice P. Borderline tumors of the ovary and fertility [J]. Eur J Cancer, 2006,42:149-158.
  • 7Winter WE 3rd, Kucera PR, Rodgers W,et al. Surgical staging in patients with ovarian tumors of low malignant potential [J]. Obstet Gynecol, 2002,100:671-676.
  • 8Fauvet R, Boccara J, Dufbnmet C, et al. Laparoscopic manage- ment of borderline ovarian tumors: results of a French muhi- center study [ J ]. Ann Oncol, 2005, 16:403-410.
  • 9Fischerova D, Zikan M, Dundr P, et al. Diagnosis, treatment, and follow-up of borderline ovarian tumors [J]. Oncologist, 2012,17:1515-1533.

同被引文献52

  • 1段微,范逢晓.保留生育功能手术对卵巢交界性肿瘤临床治疗效果的影响[J].中国实用妇科与产科杂志,2006,22(6):449-450. 被引量:11
  • 2唐军,赖娟,耿京,吕君.术前诊断卵巢交界性肿瘤的超声特征[J].中国妇产科临床杂志,2007,8(3):172-174. 被引量:18
  • 3Mikami Y. Paradigm shift in ovarian tumor pathology from the view ofgenomic abnormalities [J]. Gan To Kagaku Ryoho, 2016,43(3) :286-289.
  • 4孙但窈.卵巢交界性肿瘤病理及影响预后相关因素分析[D],乌鲁木齐:新疆医科大学.2015.
  • 5Hashmi AA, Hussain ZF,Bhagwani AR,et al. Clinico- pathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors:an institutional perspective [J]. BMC Res Notes, 2016,9(1) : 205.
  • 6Li X, Yang J,Wang X, et al. Role of TWIST2, E -cad- herin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression [J]. Eur J Gynaecol Oncol, 2016,37(1 ) : 100-108.
  • 7Tiwari RK, Saha K, Mukhopadhyay D, et al. Evaluation of preoperative serum levels of CA125 and Expression of p53 in ovarian neoplasms:a prospective clinicopathologi- cal study in a Tertiary Care Hospital [J]. J Obstet Gynaeeol India, 2016,66(2) : 107-114.
  • 8Yoshida A, Derchain SF,Pitta DR,et al. Comparing the Copenhagen Index (CPH-I)and Risk of Ovarian Malig- nancy Algorithm(ROMA) :two equivalent ways to differ- entiate malignant from benign ovarian tumors before surgery? [J]. Gynecol Oncol,2016,140(3) :481-485.
  • 9林仲秋.FIGO/IGCS妇科恶性肿瘤分期及临床实践指南(六):卵巢癌[J].国际妇产科学杂志,2008,35(6):459-461. 被引量:48
  • 10梁旭东,曾浩霞,李艺,祝洪澜,沈丹华,廖晓云,崔恒,魏丽惠.卵巢交界性上皮性肿瘤临床分析[J].中国妇产科临床杂志,2010,11(6):406-409. 被引量:14

引证文献6

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部